Show simple item record

dc.contributor.author Ács, Balázs
dc.contributor.author Madaras, Lilla
dc.contributor.author Tőkés, Anna-Mária
dc.contributor.author Kovács, Attila
dc.contributor.author Kovacs E
dc.contributor.author Ozsvari-Vidakovich M
dc.contributor.author Karaszi A
dc.contributor.author Birtalan, Ede
dc.contributor.author Dank, Magdolna
dc.contributor.author Szász, Attila Marcell
dc.contributor.author Kulka, Janina
dc.date.accessioned 2018-06-25T07:19:27Z
dc.date.available 2018-06-25T07:19:27Z
dc.date.issued 2017
dc.identifier 85021105527
dc.identifier.citation pagination=69-77; journalVolume=35; journalTitle=BREAST;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/5148
dc.identifier.uri doi:10.1016/j.breast.2017.06.013
dc.description.abstract PURPOSE: We aimed to compare the immunohistochemical expression of PD-1, PD-L1 and CTLA-4 of pregnancy-related breast cancer (PRBC) and early onset non-PRBC (YWBC), and their prognosis prediction potential was correlated to that of conventional clinicopathological factors. METHODS: Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. Immune-checkpoint markers (ICM) were evaluated with immunohistochemistry (IHC) on whole slides using the following antibodies: PD-1 (NAT-105), PD-L1 (28-8) and CTLA-4 (F-8). IHC score was defined as the percentage of positive cells, assessed separately among tumor cells, intratumoral lymphocytes and peritumoral lymphocytes. RESULTS: The optimal threshold of PD-L1 expression of tumor cells occurred at 10% for overall survival (OS, AUC = 0.847, p = 0.009), and at 1% for disease-free survival (DFS, AUC = 0.795, p = 0.010). For PD-L1 expression on intratumoral lymphocytes, the optimal cut-off was 1% (AUC = 0.763, p = 0.048). Considering PD-1, PD-L1 and CTLA-4 expression, no significant difference occurred between PRBC and YWBC (p > 0.05 for all comparisons). PD-1, PD-L1 expressed on peritumoral lymphocytes and CTLA-4 failed, but PD-L1 expressed on tumor cells and on intratumoral lymphocytes was suitable to distinguish patient cohorts with different OS and DFS (p </= 0.011 for all comparisons). Higher PD-L1 expression was associated with poor prognosis. PD-L1 expressed on tumor cells represented an independent association with OS (p = 0.023) and DFS (p = 0.032). CONCLUSIONS: Our results suggest that PRBC and YWBC do not differ in the expression of PD-1, PD-L1 and CTLA-4. However, our findings emphasize the relevance of PD-L1 expression in early-onset breast cancer, as an independent negative predictor of prognosis.
dc.relation.ispartof urn:issn:0960-9776
dc.title PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study
dc.type Journal Article
dc.date.updated 2018-03-13T13:39:22Z
dc.language.rfc3066 en
dc.identifier.mtmt 3248675
dc.identifier.wos 000410705500012
dc.identifier.pubmed 28651116
dc.contributor.department SE/AOK/I/II. Sz. Patológiai Intézet
dc.contributor.department SE/AOK/I/IISZPI/MTA-SE Molekuláris Onkológia Kutatócsoport
dc.contributor.department SE/AOK/K/Fül-Orr-Gégészeti és Fej-Nyaksebészeti Klinika
dc.contributor.department SE/AOK/K/Onkológiai Központ
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account